Search Results
Aug 14, 2026, 18:15 ET Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC
with baseless claims to create a buying frenzy among retail investors. The promoters circulated fabricated rumors that Gilead Sciences, Inc. (NASDAQ: GILD) ("Gilead") was preparing to acquire or partner with the Company with a transaction date of August 6, 2025.According to the complaint, on July
More news about: Robbins LLP
Aug 07, 2026, 07:00 ET PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL)
with baseless claims to create a buying frenzy among retail investors. The promoters circulated fabricated rumors that Gilead Sciences, Inc. (NASDAQ: GILD) ("Gilead") was preparing to acquire or partner with the Company with a transaction date of August 6, 2025.According to the complaint, on July
More news about: Robbins LLP
Apr 07, 2026, 10:30 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), through a sale to Gilead Sciences [Nasdaq: GILD]. Tubulis' lead asset, TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant
More news about: EQT
Apr 07, 2026, 10:27 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), through a sale to Gilead Sciences [Nasdaq: GILD]. Tubulis' lead asset, TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant
More news about: EQT
Mar 19, 2026, 10:00 ET Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ: ONCY), Gilead Sciences (NASDAQ: GILD), enGene Holdings (NASDAQ: ENGN), TScan Therapeutics (NASDAQ: TCRX), and Day One Biopharmaceuticals (NASDAQ: DAWN) (soon to be Servier),
More news about: USA News Group
Mar 03, 2026, 09:00 ET Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
pipelines across multiple indications include Oncolytics Biotech (NASDAQ: ONCY), Eli Lilly (NYSE: LLY), Gilead Sciences (NASDAQ: GILD), Arcellx (NASDAQ: ACLX), and Merck (NYSE: MRK).
More news about: USA News Group
Feb 24, 2026, 10:58 ET Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
Biotech (NASDAQ: ONCY), Exelixis (NASDAQ: EXEL), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Gilead Sciences (NASDAQ: GILD).
More news about: USA News Group
Dec 17, 2025, 11:19 ET Wood Partners and Clarion Partners Break Ground on Alta Metro Center in Aurora, Colorado
successfully completed delivery of the first phase of The Gild, a best-in-class apartment community located adjacent to the Alta Metro Center site. With thoughtfully designed residences, modern amenities, and a commitment to resident comfort, The Gild is quickly establishing itself as a desirable address
More news about: Wood Partners
Dec 15, 2025, 16:18 ET Alger Russell Innovation Index Updates for Fourth Quarter 2025
Gilead Sciences, Inc.GILDDeletion
More news about: Alger
Oct 21, 2025, 08:05 ET The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
and Chief Medical Officer at Exelixis (Nasdaq: EXEL). Prior to that, she served as Vice President of Oncology Clinical Development at Gilead (Nasdaq: GILD), including leading the expansion of the magrolimab program in hematologic and solid tumor indications. Dr. O'Hear started her industry career
More news about: Institute for Follicular Lymphoma Innovation (IFLI)
Sep 15, 2025, 16:25 ET Alger Russell Innovation Index Updates for Third Quarter 2025
Gilead Sciences, Inc. GILD Addition
More news about: Alger